Prostate cancer has the second highest incidence among cancers in men worldwide and is
the second leading cause of cancer deaths of men in the United States. Although androgen …

Background The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-
binding domain, which is the target of enzalutamide and abiraterone, but remains …

Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …

Background Abiraterone acetate plus prednisone significantly improved radiographic
progression-free survival compared with placebo plus prednisone in men with …

Background Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in
men with metastatic castration-resistant prostate cancer in whom the disease has …

The number of cancer survivors continues to increase due to the aging and growth of the
population and improvements in early detection and treatment. In order for the public health …

Abstract Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …

Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall
survival (OS) is significantly improved with cabazitaxel versus mitoxantrone after prior …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …